Cargando…
Identification of Prostaglandin F2 Receptor Negative Regulator (PTGFRN) as an internalizable target in cancer cells for antibody-drug conjugate development
Antibody-drug conjugates (ADC) are effective antibody-based therapeutics for hematopoietic and lymphoid tumors. However, there is need to identify new targets for ADCs, particularly for solid tumors and cancers with unmet needs. From a hybridoma library developed against cancer cells, we selected th...
Autores principales: | Marquez, Jorge, Dong, Jianping, Dong, Chun, Tian, Changsheng, Serrero, Ginette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840024/ https://www.ncbi.nlm.nih.gov/pubmed/33503070 http://dx.doi.org/10.1371/journal.pone.0246197 |
Ejemplares similares
-
Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene
por: Mala, Uchurappa, et al.
Publicado: (2022) -
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells
por: Abrhale, Tesfom, et al.
Publicado: (2011) -
Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells
por: Kim, Wes E., et al.
Publicado: (2016) -
Identification of a Novel Prostaglandin F(2α) Synthase in Trypanosoma brucei
por: Kubata, Bruno Kilunga, et al.
Publicado: (2000) -
Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism
por: Wang, Yi-Jun, et al.
Publicado: (2023)